STOCK TITAN

Harrow, Inc. - HROW STOCK NEWS

Welcome to our dedicated page for Harrow news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.

Harrow Health, Inc. (NASDAQ: HROW) is a leading eyecare pharmaceutical company dedicated to developing, producing, and distributing medications that address unmet medical needs, primarily within the United States. The company’s core business revolves around the creation of ophthalmology-based formulations, providing both sterile and non-sterile compounded medications to physicians and patients.

Harrow Inc. is at the forefront of innovative therapeutics, focusing on the treatment of ocular surface diseases. The firm's product portfolio includes prominent drug candidates such as SURF-100 and SURF-200, which are topical eye drops; SURF-300, an oral capsule aimed at treating ocular surface diseases and dry eye disease (DED) symptoms; and Klarity drops, designed for the protection and rehabilitation of ocular surface pathology in DED patients.

Additionally, Harrow, Inc. is known for its non-intravenous sedation and anesthesia products for various medical procedures. MELT-100, for instance, is a sublingual drug facilitating conscious sedation during cataract surgery, and MAY-66 is utilized for alleviating symptoms associated with Peyronie’s disease.

Harrow Health's commitment goes beyond innovation; it strives to improve accessibility and affordability of eyecare pharmaceuticals for millions of Americans. Through strategic partnerships and ongoing projects, Harrow, Inc. continues to enhance its capabilities in the eyecare sector, firmly positioning itself as a trusted name among U.S. eyecare professionals.

Stay updated with the latest developments, financial reports, and news on Harrow, Inc. to understand how this company is shaping the future of ophthalmic care.

Rhea-AI Summary

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, will attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting in Stockholm, Sweden, from July 17-20, 2024.

The meeting gathers top retina specialists, researchers, and industry leaders to discuss the latest advancements in retinal health.

Harrow plans to showcase its expanding portfolio, including IHEEZO®, a novel anesthetic gel for ocular surface anesthesia, and provide updates on the relaunch of TRIESENCE®, used for vitrectomy and treating posterior uveitis.

The company's participation aims to build a strong retina franchise and demonstrate its commitment to serving the U.S. retina community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences
-
Rhea-AI Summary

Harrow (Nasdaq: HROW) has entered into an agreement with Apexus to offer its products, including IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, through the 340B Prime Vendor Program starting July 1, 2024. The 340B PVP, managed by Apexus, aims to enhance purchasing power for U.S. hospitals and ensure access to discounted medications. Additional Harrow products included are VIGAMOX®, a bacterial conjunctivitis treatment, and ILEVRO®, an NSAID for ocular pain and inflammation. This agreement aims to open access to Harrow's products for the U.S. hospital market, significantly impacting the 44% of hospitals participating in the program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary

Harrow (Nasdaq: HROW) has successfully manufactured the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, an FDA-approved corticosteroid for ocular surgeries and inflammatory conditions. The remaining two PPQ batches are scheduled, and if all batches meet specifications, TRIESENCE will relaunch in 2024. TRIESENCE has been on the FDA Drug Shortage List for over five years, with no inventory available in the U.S. for over two years. Harrow is committed to quickly building commercial inventories, though initial supplies may not meet market demand. Pre-commercial activities and discussions with strategic accounts for pre-orders are underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.92%
Tags
none
Rhea-AI Summary

Melt Pharmaceuticals has dosed the first patient in its Phase 3 clinical trial for MELT-300, a non-IV, non-opioid sedation tablet, targeting procedural sedation during cataract surgery. MELT-300 combines midazolam and ketamine in a sublingual, fast-dissolving format. The trial is a randomized, double-blind study involving 528 patients across 14 clinical sites, comparing MELT-300 to sublingual midazolam and a placebo. Previous Phase 2 trials showed MELT-300's superior efficacy. Topline results are expected in Q4 2024. CEO Dr. Larry Dillaha highlighted the innovation in sedation and potential expansion to over 100 million annual procedures in various medical fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
-
Rhea-AI Summary

Harrow (Nasdaq: HROW) announced results from its ESSENCE-2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, aimed at treating dry eye disease (DED). The 52-week study, involving 202 patients, demonstrated sustained safety and efficacy of VEVYE, with significant improvements in corneal staining, tear production, and symptomatology. Mild instillation site pain and reduced visual acuity were the most common adverse events. Only one patient withdrew due to mild ocular discomfort. 33.1% of patients rated the eye drop satisfaction at 10, and 91% rated it 5 or higher. Investigators highlighted VEVYE’s tolerability and long-term potential. Harrow’s CEO emphasized the product’s unique formulation and clinical benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
Rhea-AI Summary

Harrow (Nasdaq: HROW), a prominent North American eyecare pharmaceutical company, will participate in two investor conferences in May. The company will attend the B. Riley Securities 24th Annual Institutional Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA, on May 22-23, 2024. The event includes an in-person Fireside Chat and 1x1 investor meetings.

Harrow will also be present at the Craig-Hallum 21st Annual Institutional Investor Conference at the Depot Renaissance Hotel in Minneapolis, MN, on May 29, 2024, featuring 1x1 and small group investor meetings. Interested investors should contact their B. Riley or Craig-Hallum representative for meeting arrangements. Neither event will be webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences
Rhea-AI Summary

Harrow (Nasdaq: HROW) reported its first quarter 2024 financial results, with revenues reaching $34.6 million, a 33% increase from the prior-year quarter. Gross margin was steady at 69%, while net loss increased to $13.6 million from $6.6 million in Q1 2023. Key highlights include IHEEZO's new CMS reimbursement approval, seven new supply agreements, and new patent claims valid through 2039. VEVYE's coverage expanded to 150 million lives, and ImprimisRx returned to quarterly growth. Cash reserves totaled $76 million as of March 31, 2024, with an additional $5.5 million from recent Eton Pharmaceuticals stock sales. Harrow remains focused on expanding its dry eye and retina franchises and stabilizing ImprimisRx.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.55%
Tags
-
Rhea-AI Summary

Harrow, a U.S. eyecare pharmaceutical company, appoints Greg DiPasquale as Senior Vice President, Head of Commercial. DiPasquale brings extensive experience from companies like Regeneron and Novartis, with a track record of growing sales and revenue in the ophthalmic pharmaceutical industry. Harrow aims to leverage DiPasquale's expertise to enhance its leadership structure and drive growth in the North American market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) will release its first quarter 2024 financial results on May 13, 2024, followed by a conference call on May 14, 2024, to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
Rhea-AI Summary
Melt Pharmaceuticals, Inc. completes a Series B Preferred Stock financing of $24 million, increasing pre-money valuation by 150%. The funding will support the development of MELT-300, a non-IV, non-opioid tablet for procedural sedation. The Phase 3 program started in Q1 2024, with topline results expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none

FAQ

What does Harrow, Inc. specialize in?

Harrow, Inc. specializes in developing, producing, and selling ophthalmic pharmaceutical products and compounded medications for unmet medical needs in the U.S.

What are some key products of Harrow, Inc.?

Key products include SURF-100, SURF-200, SURF-300, Klarity drops, MELT-100, and MAY-66, which cater to various ocular surface diseases and medical procedures.

What is the significance of SURF-300?

SURF-300 is an oral capsule designed to treat patients suffering from ocular surface diseases and symptoms of dry eye disease (DED).

How does MELT-100 benefit patients?

MELT-100 is administered sublingually for conscious sedation during cataract surgery, providing a non-intravenous sedation option.

Who are the primary customers of Harrow, Inc.?

The primary customers are U.S. eyecare professionals and their patients, benefiting from Harrow, Inc.'s comprehensive portfolio of affordable pharmaceutical products.

What makes Harrow, Inc. unique in the eyecare pharmaceutical sector?

Harrow, Inc. stands out due to its focus on unmet medical needs, innovative product portfolio, and commitment to accessibility and affordability in the ophthalmic care market.

How does Harrow, Inc. contribute to the treatment of dry eye disease (DED)?

Products like SURF-300 and Klarity drops are specifically designed to treat and manage symptoms of dry eye disease, protecting and rehabilitating the ocular surface.

Where is Harrow, Inc. based?

Harrow, Inc. operates primarily in the United States, serving the American market with its pharmaceutical innovations.

What recent achievements has Harrow, Inc. made?

Recent achievements include the development and commercialization of various therapeutics for ocular surface diseases and advancements in non-intravenous sedation products.

How can investors stay updated with Harrow, Inc.'s latest news?

Investors can stay updated by following financial reports, press releases, and news updates provided by the company and credible financial news sources.

Harrow, Inc.

Nasdaq:HROW

HROW Rankings

HROW Stock Data

884.90M
35.38M
14.08%
60.3%
13.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NASHVILLE